AstraZeneca, Peregrine in clinical trial collaboration for drug to treat multiple solid tumors

Anglo-Swedish drug major AstraZeneca (LSE: AZN) on Monday said it has partnered with Peregrine Pharmaceuticals (Nasdaq: PPHM) for early stage trials for a drug to treat in multiple solid tumors.

The company in a statement said it will test the safety and efficacy of Peregrine’s drug candidate bavituximab with its own durvalumab in combination with chemotherapy as a potential treatment in various solid tumors.

Robert Iannone, head of immuno-oncology, at AstraZeneca, said: “We believe that combination therapy in immuno-oncology has the potential to be a novel and highly effective approach to treating cancer. Our partnership with Peregrine provides the opportunity to explore an exciting, novel combination that could deliver important clinical benefit to patients across a range of cancers.”